Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05067621 · ClinicalTrials.gov registry record · Phase 2

Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease

A Phase 2 study of Type 2 Diabetes Mellitus and Obesity, Childhood, sponsored by Yale University.

Recruiting
Registry status
Phase 2
Development phase
60
Enrollment target
1
Study location

NCT05067621 is a Phase 2 study of Type 2 Diabetes Mellitus and Obesity, Childhood that is actively recruiting participants, run by Yale University. The registered enrollment target is 60 participants, below the 2,748-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05067621, a Phase 2 study of Type 2 Diabetes Mellitus and Obesity, Childhood, is actively recruiting participants, sponsored by Yale University.

RECRUITING
Registry status
Phase 2
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to understand the role of GLP-1 in the pathogenesis of T2D in youth and explore their potential salutary effects and ability to delay the progressive loss of ß-cell function and reduce hepatic steatosis in youth with prediabetes/new onset T2D and NAFLD.

Interventions

  • DRUG Placebo
  • DRUG Semaglutide Pen Injector

Study Locations (1)

Connecticut

  • Pediatric Diabetes Center - New Haven

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2023-07-17
Est. Completion 2027-01
Phase Phase 2

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT05067621

The ClinicalTrials.gov registry entry for NCT05067621 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,748-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (98% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05067621 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT05067621 about?

NCT05067621 is a clinical study titled "Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease". The purpose of this study is to understand the role of GLP-1 in the pathogenesis of T2D in youth and explore their potential salutary effects and ability to delay the progressive loss of ß-cell function and reduce hepatic steatosis in youth with prediabetes/new onset T2D and NAFLD.

What is the current status of trial NCT05067621?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2023-07-17. Estimated completion is 2027-01.

What conditions does trial NCT05067621 study?

This clinical trial studies the following conditions: Type 2 Diabetes Mellitus, Obesity, Childhood, Non-alcoholic Fatty Liver Disease, Impaired Glucose Tolerance.

What interventions are being tested in trial NCT05067621?

The interventions under investigation include: Placebo (DRUG), Semaglutide Pen Injector (DRUG).

Who is sponsoring clinical trial NCT05067621?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05067621 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 2 Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.